Literature DB >> 20859108

Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines.

Dawn I Velligan1, Peter J Weiden, Martha Sajatovic, Jan Scott, Daniel Carpenter, Ruth Ross, John P Docherty.   

Abstract

Poor adherence to medication can have devastating consequences for patients with serious mental illness. The literature review and recommendations in this article are reprinted from The Expert Consensus Guideline Series: Adherence Problems in Patients with Serious and Persistent Mental Illness, published in 2009. The expert consensus survey (39 questions, 521 options) on adherence problems in schizophrenia and bipolar disorder was completed by 41 experts in 2008. This article first reviews the literature on interventions aimed at improving adherence. It then presents the experts' recommendations for targeting factors that can contribute to nonadherence and relates them to the literature. The following psychosocial/programmatic and pharmacologic interventions were rated first line for specific problems that can lead to nonadherence: ongoing symptom/ side-effect monitoring for persistent symptoms or side effects; services targeting logistic problems; medication monitoring/environmental supports (e.g., Cognitive Adaptation Training, assertive community treatment) for lack of routines or cognitive deficits; and adjusting the dose or switching to a different oral antipsychotic for persistent side effects (also high second-line for persistent symptoms). Among pharmacologic interventions, the experts gave high second-line ratings to switching to a long-acting antipsychotic when lack of insight, substance use, persistent symptoms, logistic problems, lack of routines, or lack of family/ social support interfere with adherence and to simplifying the treatment regimen when logistic problems, lack of routines, cognitive deficits, or lack of family/social support interfere with adherence. Psychosocial/programmatic interventions that received high second-line ratings in a number of situations included medication monitoring/environmental supports, patient psychoeducation, more frequent and/or longer visits if possible, cognitive behavioral therapy (CBT), family-focused therapy, and services targeting logistic problems. It is important to identify specific factors that may be contributing to a patient's adherence problems in order to customize interventions and to consider using a multifaceted approach since multiple problems may be involved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20859108     DOI: 10.1097/01.pra.0000388626.98662.a0

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  47 in total

Review 1.  Medication adherence in schizophrenia.

Authors:  Francisco Javier Acosta; José Luis Hernández; José Pereira; Judit Herrera; Carlos J Rodríguez
Journal:  World J Psychiatry       Date:  2012-10-22

2.  Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

Authors:  Pál Czobor; Richard A Van Dorn; Leslie Citrome; Rene S Kahn; W Wolfgang Fleischhacker; Jan Volavka
Journal:  Eur Neuropsychopharmacol       Date:  2015-04-30       Impact factor: 4.600

Review 3.  Management of adverse effects of mood stabilizers.

Authors:  Andrea Murru; Dina Popovic; Isabella Pacchiarotti; Diego Hidalgo; Jordi León-Caballero; Eduard Vieta
Journal:  Curr Psychiatry Rep       Date:  2015-08       Impact factor: 5.285

Review 4.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

5.  Family practice enhancements for patients with severe mental illness.

Authors:  Patricia Pastore; Kim S Griswold; Gregory G Homish; Robert Watkins
Journal:  Community Ment Health J       Date:  2012-07-24

Review 6.  [Motivational interviewing : A possibility for doctor-patient communication in schizophrenia?]

Authors:  Jens Reimer; Jens Kuhn; Rita Wietfeld; Wolfgang Janetzky; Karolina Leopold
Journal:  Nervenarzt       Date:  2019-11       Impact factor: 1.214

7.  Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.

Authors:  Jimmi Nielsen; Signe O W Jensen; Rasmus B Friis; Jan B Valentin; Christoph U Correll
Journal:  Schizophr Bull       Date:  2014-09-01       Impact factor: 9.306

8.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 9.  Adherence to cognitive behavioral therapy for insomnia: a systematic review.

Authors:  Ellyn E Matthews; J Todd Arnedt; Michaela S McCarthy; Leisha J Cuddihy; Mark S Aloia
Journal:  Sleep Med Rev       Date:  2013-04-17       Impact factor: 11.609

10.  Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder.

Authors:  Louisa G Sylvia; Aleena Hay; Michael J Ostacher; David J Miklowitz; Andrew A Nierenberg; Michael E Thase; Gary S Sachs; Thilo Deckersbach; Roy H Perlis
Journal:  J Clin Psychopharmacol       Date:  2013-06       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.